Back to search results

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Abroad (travel likely)RecruitingPHASE1

Conditions

Ovarian Cancer · Cholangiocarcinoma Recurrent · Mesothelioma, Malignant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Ashley O'Neil, MPH, LSSWB, CCRC) · Ashley.ONeil@moffitt.org · 813-745-5240
    Contact: Principal Investigator (Ben Creelan, MD)

  • University of Kansas Cancer Center, Westwood, Kansas, United States

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Andrea Standish) · andrea.standish@pennmedicine.upenn.edu · 215-662-2419
    Contact: Principal Investigator (Janos Tanyi, MD, PhD)

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Zheng Zhang) · ZZhang11@mdanderson.org · 832-729-0975
    Contact: Principal Investigator (Mehmet Altan, MD)

  • University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Cancer Connect) · CancerConnect@uwhealth.org · 800-622-8922
    Contact: Principal Investigator (Zhubin Gahvari, MD)
View source on ClinicalTrials.gov(opens in a new tab)